Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 260

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 260
---
 If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. 

12. Employee BenefitsThe Company offers a 401(k) plan (401(k) Plan) for all employees who have met certain eligibility requirements. Under the 401(k) Plan, employees may elect to contribute a portion of their eligible compensation, subject to certain limitations. The Company did not make any matching employer contributions to the 401(k) Plan for the years ended December 31, 2024 and 2023.

13. Segment InformationThe Company reports segment information based on the management approach, which reflects the way in which the internal reporting is used by the chief operating decision maker (“CODM”) to analyze performance, make decisions and allocate resources. The CODM is the Company’s Chief Executive Officer.The Company manages its operations as a single reportable segment, which includes all activities related to the research, development, and potential future commercialization of its small molecule drug development candidates. The CODM assesses performance and decides how to allocate resources based on net loss (presented in the Statements of Operations and Comprehensive Loss). The measure of segment assets is reported on the Balance Sheets as total assets. All long-lived assets are located in the United States. 

136

The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, to the Company’s total net loss in the Statements of Operations and Comprehensive Loss (in thousands):   

        Year endedDecember 31,

        2024

        2023

        Research and development expenses:

              External research and development expenses by program:

              TYRA-300ACH
         
        $
        7,718

        $
        5,268

              TYRA-300mUC

        14,319

        15,613

              TYRA-430

        5,677

        4,987

              TYRA-200

        4,969

        4,418

              FGFR discovery

        8,321

        5,492

              Other development programs

        2,537

        2,448

              Unallocated research and development expenses:

              Personnel costs